focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

Wed, 03rd Jan 2024 07:54

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

This is also ahead of two key data releases in the US later, particularly the latest meeting minutes from the US Federal Reserve this evening, which will provide investors insight into the central bank's thinking on the future of US interest rates.

Prior to this, the Institute of Supply Management's manufacturing PMI for the US is released in the afternoon.

"Markets turned cautious ahead of today's [Federal Open Market Committee] minutes, US JOLT's job openings number, and the ISM manufacturing index. Markets have rallied over the past few weeks, and the dollar has come under considerable pressure as markets price in six rate cuts by the Fed this year," said TreasuryOne analyst Andre Cilliers.

"The Fed is only forecasting three cuts at this stage, and we saw some short dollar covering yesterday while bonds and equities were sold off."

In UK corporate news, both Wizz Air and Ryanair reported increased passenger numbers in December and across 2023.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: called down 1.0 point at 7,720.52

----------

Hang Seng: down 1.4% at 7,523.20

Nikkei 225: financial markets in Japan closed for New Year holiday

S&P/ASX 200: closed down 1.4% at 7,523.20

----------

DJIA: closed up 25.50 points, or 0.1%, at 37,715.04

S&P 500: closed down 27.00 points, or 0.6%, at 4,742.83

Nasdaq Composite: closed down 245.41 points, or 1.6%, to 14,765.94

----------

EUR: up at USD1.0959 (USD1.0955)

GBP: up at USD1.2635 (USD1.2620)

USD: up at JPY142.34 (JPY141.74)

Gold: down at USD2,062.16 per ounce (USD2,064.66)

(Brent): down at USD75.81 a barrel USD77.75)

(changes since previous London equities close)

----------

ECONOMICS

----------

Wednesday's key economic events still to come:

09:55 CET Germany unemployment

10:00 EST US ISM manufacturing PMI

14:00 EST US Federal Reserve meeting minutes

----------

The Israeli army has said it is "prepared for any scenario" after a strike in Beirut that killed Hamas's deputy chief, stoking fears the war in the Gaza Strip could boil over into wider regional conflict. Israeli army spokesperson Daniel Hagari did not directly comment on the killing, but said afterwards that the military was in "very high state of readiness in all arenas, in defence and offence. We are highly prepared for any scenario." Israel has previously announced the deaths in Gaza of Hamas commanders and officials during the war, but Aruri is the most high-profile figure to be killed, and his death came in the first strike on the Lebanese capital since hostilities began.

----------

BROKER RATING CHANGES

----------

Jefferies cuts AstraZeneca to 'hold' (buy) - price target 11,000 (12,500) pence

----------

Jefferies raises GSK to 'buy' (hold) - price target 1,900 (1,550) pence

----------

COMPANIES - FTSE 250

----------

Wizz Air said it carried 5.0 million passengers in December, up 19% from a year earlier, at a load factor of 82% from 85%. Across 2023, it carried 60.3 million passengers, up 32% from 45.7 million in 2022, at a load factor of 91% from 87%. Capacity in December rose 22% to 6.0 million passengers from 5.0 million a year earlier, while across 2023, capacity rose 26% to 66.4 million from 52.7 million. The airline said it continued to grow its network and improve its customer offering in December, including Wizz Air Abu-Dhabi doubling the number of flights to 15,000 and carrying more than three million passengers.

----------

OTHER COMPANIES

----------

Budget airline Ryanair said it carried 12.5 million passengers in December, up 8.7% from 11.5 million passengers a year earlier, at a load factor of 91% from 92%. It said it operated over 72,500 flights in December, while over 900 flights were cancelled due to the Israel/Gaza conflict. Across 2023, it carried 181.8 million passengers, up 13% from 160.4 million in 2022, at a load factor of 94% from 92%.

----------

Drug discovery company C4X Discovery said it has received a milestone payment of USD11 million from FTSE 100-listed pharmaceutical firm AstraZeneca, triggered by pre-clinical progress of C4X Discovery's NFT2 Activator programme. AstraZeneca is developing C4X Discovery's former programme to deliver an oral therapy for the treatment of inflammatory and respiratory diseases, with a lead focus on chronic respiratory disease. As announced under the terms of the licencing agreement in November 2022, C4X Discovery received an initial USD2 million upfront payment from AstraZeneca and is potentially entitled to receive up to USD400 million in preclinical, clinical development and commercial milestones, as well as tiered mid-single digit royalties on future sales. C4X Discovery Clive Dix commented: "This significant preclinical milestone payment marks the progress AstraZeneca has made in driving the NRF2 Activator programme forward. NRF2 is a challenging target and this achievement provides further validation of our ability to generate differentiated, quality molecules in immuno-inflammation."

----------

Chill Brands unveiled product launch plans and regulatory initiatives for the first quarter of 2024. As previously announced, the CBD products company received a number of material purchase orders during the fourth quarter of 2023. It is now in the process of fulfilling those purchase orders and expects to have delivered all initial inventory during January 2024. Chill ZERO nicotine-free vape products will launch into initial WH Smith travel locations, Morrisons stores, and roadside retail stores operating on Shell, BP and Esso branded forecourts during January 2024 with the rollout continuing incrementally throughout the first quarter. Chill Brands said it will also take steps to address regulatory concerns on balancing the "positive impact of vaping as a harm reduction tool with the need to protect children and the environment". It plans to do this by participating in a recycling scheme, to focus on "appropriate merchandising and age verification to ensure express compliance with existing and future regulations at all points of the supply chain", and to use more "conscious" design and flavour choices that indicate its products are "solely intended for adult consumers".

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.